Literature DB >> 25066126

Intratumor DNA methylation heterogeneity reflects clonal evolution in aggressive prostate cancer.

David Brocks1, Yassen Assenov1, Sarah Minner2, Olga Bogatyrova1, Ronald Simon2, Christina Koop2, Christopher Oakes1, Manuela Zucknick3, Daniel Bernhard Lipka4, Joachim Weischenfeldt5, Lars Feuerbach6, Richard Cowper-Sal Lari7, Mathieu Lupien8, Benedikt Brors6, Jan Korbel9, Thorsten Schlomm10, Amos Tanay11, Guido Sauter2, Clarissa Gerhäuser1, Christoph Plass12.   

Abstract

Despite much evidence on epigenetic abnormalities in cancer, it is currently unclear to what extent epigenetic alterations can be associated with tumors' clonal genetic origins. Here, we show that the prostate intratumor heterogeneity in DNA methylation and copy-number patterns can be explained by a unified evolutionary process. By assaying multiple topographically distinct tumor sites, premalignant lesions, and lymph node metastases within five cases of prostate cancer, we demonstrate that both DNA methylation and copy-number heterogeneity consistently reflect the life history of the tumors. Furthermore, we show cases of genetic or epigenetic convergent evolution and highlight the diversity in the evolutionary origins and aberration spectrum between tumor and metastatic subclones. Importantly, DNA methylation can complement genetic data by serving as a proxy for activity at regulatory domains, as we show through identification of high epigenetic heterogeneity at androgen-receptor-bound enhancers. Epigenome variation thereby expands on the current genome-centric view on tumor heterogeneity.
Copyright © 2014 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 25066126     DOI: 10.1016/j.celrep.2014.06.053

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  104 in total

Review 1.  Single-cell epigenomics: techniques and emerging applications.

Authors:  Omer Schwartzman; Amos Tanay
Journal:  Nat Rev Genet       Date:  2015-10-13       Impact factor: 53.242

2.  Linkage disequilibrium analysis of allelic heterogeneity in DNA methylation.

Authors:  Daisuke Saito; Mikita Suyama
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

Review 3.  The evolution of tumour phylogenetics: principles and practice.

Authors:  Russell Schwartz; Alejandro A Schäffer
Journal:  Nat Rev Genet       Date:  2017-02-13       Impact factor: 53.242

Review 4.  Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2019-07-30

Review 5.  Genetic and epigenetic heterogeneity in acute myeloid leukemia.

Authors:  Sheng Li; Christopher E Mason; Ari Melnick
Journal:  Curr Opin Genet Dev       Date:  2016-05-07       Impact factor: 5.578

6.  Identification of DNA methylation changes at cis-regulatory elements during early steps of HSC differentiation using tagmentation-based whole genome bisulfite sequencing.

Authors:  Daniel B Lipka; Qi Wang; Nina Cabezas-Wallscheid; Daniel Klimmeck; Dieter Weichenhan; Carl Herrmann; Amelie Lier; David Brocks; Lisa von Paleske; Simon Renders; Peer Wünsche; Petra Zeisberger; Lei Gu; Simon Haas; Marieke Ag Essers; Benedikt Brors; Roland Eils; Andreas Trumpp; Michael D Milsom; Christoph Plass
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

7.  The Proteogenomic Landscape of Curable Prostate Cancer.

Authors:  Ankit Sinha; Vincent Huang; Julie Livingstone; Jenny Wang; Natalie S Fox; Natalie Kurganovs; Vladimir Ignatchenko; Katharina Fritsch; Nilgun Donmez; Lawrence E Heisler; Yu-Jia Shiah; Cindy Q Yao; Javier A Alfaro; Stas Volik; Anna Lapuk; Michael Fraser; Ken Kron; Alex Murison; Mathieu Lupien; Cenk Sahinalp; Colin C Collins; Bernard Tetu; Mehdi Masoomian; David M Berman; Theodorus van der Kwast; Robert G Bristow; Thomas Kislinger; Paul C Boutros
Journal:  Cancer Cell       Date:  2019-03-18       Impact factor: 31.743

8.  Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories.

Authors:  Clarissa Gerhauser; Francesco Favero; Thomas Risch; Ronald Simon; Lars Feuerbach; Yassen Assenov; Doreen Heckmann; Nikos Sidiropoulos; Sebastian M Waszak; Daniel Hübschmann; Alfonso Urbanucci; Etsehiwot G Girma; Vladimir Kuryshev; Leszek J Klimczak; Natalie Saini; Adrian M Stütz; Dieter Weichenhan; Lisa-Marie Böttcher; Reka Toth; Josephine D Hendriksen; Christina Koop; Pavlo Lutsik; Sören Matzk; Hans-Jörg Warnatz; Vyacheslav Amstislavskiy; Clarissa Feuerstein; Benjamin Raeder; Olga Bogatyrova; Eva-Maria Schmitz; Claudia Hube-Magg; Martina Kluth; Hartwig Huland; Markus Graefen; Chris Lawerenz; Gervaise H Henry; Takafumi N Yamaguchi; Alicia Malewska; Jan Meiners; Daniela Schilling; Eva Reisinger; Roland Eils; Matthias Schlesner; Douglas W Strand; Robert G Bristow; Paul C Boutros; Christof von Kalle; Dmitry Gordenin; Holger Sültmann; Benedikt Brors; Guido Sauter; Christoph Plass; Marie-Laure Yaspo; Jan O Korbel; Thorsten Schlomm; Joachim Weischenfeldt
Journal:  Cancer Cell       Date:  2018-12-10       Impact factor: 31.743

Review 9.  Sentinel node evaluation in prostate cancer.

Authors:  Ramkishen Narayanan; Timothy G Wilson
Journal:  Clin Exp Metastasis       Date:  2018-09-05       Impact factor: 5.150

10.  [Systematic analysis of treatment results as a quality control instrument using the example of a large European center].

Authors:  B Beyer; H Huland; M Graefen
Journal:  Urologe A       Date:  2015-11       Impact factor: 0.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.